Heparin-Induced Thrombocytopenia: Pathophysiology and Management CME

Robert L. Levine, MD, FCCP; Kenneth A. Bauer, MD Author Information and Disclosures

Release Date: February 11, 2008; Valid for credit through February 11, 2009

Credits Available
Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians

This program is based on a symposium presented at the Annual Meeting of the American College of Chest Physicians October 23-25, 2007, in Chicago, Illinois.

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Contents of This CME Activity

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Copyright © 2008 The France Foundation.
GlaxoSmithKline
Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Describe the pathophysiology of heparin-induced thrombocytopenia (HIT) and its clinical course;
  2. Describe the risk factors for HIT;
  3. Discuss the best practices for diagnosis, management, and prevention of HIT.
Authors and Disclosures
Robert L. Levine, MD, FCCP
Disclosure: Dr. Levine has received grants and/or research support from Boehringer Ingelheim, GlaxoSmithKline, and Sanofi-Aventis. He has also served as a consultant and received honoraria from GlaxoSmithKline.

Kenneth A. Bauer, MD
Disclosure: Dr. Bauer has received grants and/or research support from Bayer Healthcare. He has served as a consultant for Bayer Healthcare, Bristol Myers-Squibb, Eisai, and Portola Pharmaceuticals. He has received honoraria from Bayer Healthcare, GlaxoSmithKline, and Sanofi-Aventis.
 
The France Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The France Foundation designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.